21 completed, 9 recruiting, 6 terminated, 5 not yet recruiting. 24 Phase 2, 12 Phase 3, 10 Phase 1, 4 Not applicable.
Follow Gastroesophageal Junction Cancer: new trials by email Literature Review of Gastroesophageal Junction Cancer trials Research Report on Gastroesophageal Junction Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study) Gastric Cancer, Gastroesophageal Junction Cancer | Not yet recruiting | AstraZeneca | 300 | 2026-10-31 | 2026-10-20 | |
| A Study in Greece Observing How Patients With Stomach and Esophageal Cancer Are Diagnosed and Treated in Everyday Medical Practice Gastric Cancer, Gastroesophageal Junction Cancer | Recruiting | AstraZeneca | 300 | 2026-09-30 | 2026-10-08 | |
| A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma Intratumoral 2141-V11, Nivolumab, Fluoropyrimidine - Esophageal Cancer, Advanced Esophageal Cancer | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2026-09-04 | 2026-09-14 |
| NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal Cancers Gastrointestinal Cancer, Gastric Cancer | Not yet recruiting | Peking University Cancer Hospital & Institute | 200 | 2026-09-01 | 2026-08-20 | |
| Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer PF-08634404, Chemotherapy, Nivolumab - Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer | Phase 2 / Phase 3 | Recruiting | Pfizer | 840 | 2026-05-14 | 2026-10-13 |
| Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging Pancreatic Cancer, Gastric Cancer | Not yet recruiting | Ruijin Hospital | 64 | 2026-04-15 | 2026-04-28 | |
| Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer Proximal Gastrectomy, Total Gastrectomy - Gastroesophageal Junction Cancer, Stomach Neoplasms | Not applicable | Recruiting | Nurettin Şahin | 120 | 2026-02-01 | 2026-03-20 |
| The Efficacy and Safety of Laparoscopic Proximal Gastrectomy With LPG-tbROSF Versus LTG for Localized Proximal Gastric Cancer. Laparoscopic Proximal Gastrectomy with Tubular Stomach-Based Right-Opening Single Flap Valvuloplasty (LPG-tbROSF) - Stomach Neoplasms, Adenocarcinoma - Gastroesophageal Junction (GEJ) | Not applicable | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 120 | 2026-01-01 | 2025-12-03 |
| Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Iparomlimab and Tuvonralimab (QL1706), SOX Chemotherapy - Gastric Cancer (GC), Gastroesophageal Junction Cancer | Phase 2 | Recruiting | Beijing Friendship Hospital | 32 | 2025-11-04 | 2026-01-06 |
| A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2 AZD0901 - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2 | Active not recruiting | AstraZeneca | 33 | 2025-08-29 | 2026-09-30 |
| Study for AZD4360 in Participants With Advanced Solid Tumours AZD4360 - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 31 | 2025-04-29 | 2026-07-31 |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 726 | 2025-02-27 | 2026-08-10 |
| Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer Nivolumab - Esophageal Cancer, Gastroesophageal Junction Cancer | Completed | Bristol-Myers Squibb | 64 | 2024-12-03 | 2025-05-31 | |
| A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China No drug - Gastric Cancer, Gastroesophageal Junction Cancer | Completed | Daiichi Sankyo | 805 | 2024-08-15 | 2025-08-21 | |
| Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer: Pembrolizumab plus chemotherapy (FLOT) - Gastroesophageal Junction Cancer | Phase 3 | Not yet recruiting | xiaohua li | 36 | 2024-06-01 | 2024-05-17 |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 AZD0901, Ramucirumab+ paclitaxel, Paclitaxel - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Active not recruiting | AstraZeneca | 594 | 2024-03-04 | 2026-10-15 |
| A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer Nivolumab - Gastric Cancer, Gastroesophageal Junction Cancer | Completed | Bristol-Myers Squibb | 260 | 2024-02-28 | 2025-12-04 | |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 AZD0901, 5-Fluorouracil, Leucovorin - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2 | Recruiting | AstraZeneca | 226 | 2023-12-13 | 2026-09-30 |
| CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer CA-4948, Nivolumab, Pembrolizumab - Gastric Cancer, Esophageal Cancer | Phase 1 | Recruiting | Washington University School of Medicine | 42 | 2023-06-02 | 2026-04-27 |
| Comprehensive Perioperative Program Based on Prehabilitation, Nutritional Intervention and Psychological Support for Patients With Locally Advanced Operable Oesophagogastric Cancer Cardiorespiratory fitness (FsPS), Exercises you can do on your own at home, Enhanced Recovery After Surgery ERAS - Locally Advanced Esophageal Cancer, Gastroesophageal Junction Cancer | Not applicable | Recruiting | Masaryk Memorial Cancer Institute | 60 | 2023-05-02 | 2026-06-26 |
Showing 20 of 50. Sign in to see all of them.
Stomach Neoplasms (41) · Esophageal Neoplasms (12) · Adenocarcinoma Of Esophagus (3) · Carcinoma, Non-Small-Cell Lung (3) · Biliary Tract Neoplasms (2) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma (1) · Anastomotic Leak (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1)
Digestive System Diseases (45) · Digestive System Neoplasms (45) · Gastrointestinal Diseases (45) · Neoplasms (45) · Neoplasms by Site (45) · Gastrointestinal Neoplasms (44) · Stomach Diseases (41) · Head and Neck Neoplasms (13) · Esophageal Diseases (12) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Breast Diseases (3) · Bronchial Neoplasms (3) · Carcinoma (3) · Carcinoma, Bronchogenic (3)
Trastuzumab (8) · Docetaxel (7) · Nivolumab (7) · Oxaliplatin (7) · Capecitabine (6) · Fluorouracil (6) · Leucovorin (6) · pembrolizumab (6) · Cisplatin (4) · Drug Therapy (4) · Paclitaxel (4) · Irinotecan (3) · Ramucirumab (2) · Saline Solution (2) · Afatinib (1)
AstraZeneca (7) · Memorial Sloan Kettering Cancer Center (5) · Bristol-Myers Squibb (3) · Daiichi Sankyo (2) · Hoffmann-La Roche (2) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (2) · Merck Sharp & Dohme LLC (2) · Pfizer (2) · Amgen (1) · BeiGene (1) · Beijing Friendship Hospital (1) · Chinese Academy of Medical Sciences (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Hellenic Cooperative Oncology Group (1) · Incyte Corporation (1)
United States (22) · China (21) · Japan (12) · South Korea (12) · Germany (10) · Taiwan (10) · Canada (9) · Italy (9) · United Kingdom (9) · Spain (8) · France (7) · Poland (7) · Turkey (Türkiye) (6) · Australia (5) · Brazil (5)
Salah-Eddin Al-Batran, Prof. Dr. (2) · Aiping Zhou, M.D (1) · Akos Czibere, MD, PhD (1) · David Ilson, MD (1) · Elizabeth Won, MD (1) · George Pentheroudakis, Ass.Prof (1) · Hong Yang, Ph.D., M.D. (1) · Nawel Bourayou, MD (1) · Patrick Grierson, M.D., Ph.D. (1)
PMID 15555621, PMID 1742526, PMID 17917772, PMID 19258111, PMID 21557015, PMID 21769467, PMID 22646630, PMID 23458447, PMID 23783553, PMID 23992097, PMID 24743609, PMID 25274134, PMID 26275293, PMID 26338060, PMID 26515945, PMID 26742998, PMID 26808342, PMID 28839986, PMID 30777447, PMID 33263418, PMID 33979100, PMID 34003074, PMID 34102137, PMID 35623069, PMID 35709415, PMID 36121651, PMID 36883420, PMID 36919706, PMID 37713657, PMID 38134948, PMID 38382001, PMID 39044132, PMID 39232496, PMID 39407137, PMID 40341124, PMID 40632415, PMID 40829093, PMID 41202501, PMID 41324998, PMID 41811823, PMID 42217113, PMID 9296510
2023 (2), 2014 (1), 2016 (1), 2025 (1), P30CA046934 (1)